Download PDF
TumorDiagnostik & Therapie 2018; 39(01): 33-37
DOI: 10.1055/s-0043-120712
Schwerpunkt Kolon- und Rektumkarzinome
© Georg Thieme Verlag KG Stuttgart · New York

Therapie des kolorektalen Karzinoms

Alexander Baraniskin
Further Information

Publication History

Publication Date:
01 February 2018 (online)

Also available at
    Permissions and Reprints

Die Therapie und Prognose des Darmkrebses hängen im Wesentlichen vom Stadium nach der UICC-Klassifikation ab. In den Stadien I–III werden Kolon- und Rektumkarzinom unterschiedlich behandelt. Im Stadium IV sind die Therapiestrategien größtenteils gleich.
 

  • Literatur

  • 1 Robert Koch-Institut. Krebs in Deutschland. 2011 www.rki.de
    PubMedGoogle Scholar
  • 2 Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149: 627-737
    CrossrefPubMedGoogle Scholar
  • 3 O’Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96: 1420-1425
    CrossrefPubMedGoogle Scholar
  • 4 Pox CP, Schmiegel W. German S3-guideline colorectal carcinoma. Dtsch Med Wochenschr 2013; 49 (138) 2545 doi:10.1055/s-0033–1353953
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Gray R, Barnwell J, Mc ConkeyC. et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370: 2020-2029
    CrossrefPubMedGoogle Scholar
  • 6 Benson III AB, Schrag D, Somerfield MR. et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22: 3408-3419
    CrossrefPubMedGoogle Scholar
  • 7 Shi Q, Sobrero AF, Shields AF. et al. Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. Paper presented at: American Society of Clinical Oncology Annual Meeting; June 2–6. Chicago: IL. Abstract LBA1 2017
    PubMedGoogle Scholar
  • 8 Biagi JJ, Raphael MJ, Mackillop WJ. et al. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer. JAMA 2011; 305: 2335-2342
    CrossrefPubMedGoogle Scholar
  • 9 Petrelli F, Sgroi G, Sarti E. et al. Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer: A Meta-analysis of Published Studies. Ann Surg 2016; 263: 458-464
    CrossrefPubMedGoogle Scholar
  • 10 Bujko K, Nowacki MP, Nasierowska-Guttmejer A. et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 2004; 72: 15-24
    CrossrefPubMedGoogle Scholar
  • 11 Peeters KC, Marijnen CA, Nagtegaal ID. et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007; 246: 693-701
    CrossrefPubMedGoogle Scholar
  • 12 Fong Y, Sun RL, Brennan MF. et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-321
    CrossrefPubMedGoogle Scholar
  • 13 Nordlinger B, Sorbye H, Glimelius B. et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007-1016
    CrossrefPubMedGoogle Scholar
  • 14 Primrose J, Falk S, Finch-Jones M. et al. A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wildtype patients with operable metastases from colorectal cancer. J Clin Oncol 2013 31. abstr 3504
    PubMedGoogle Scholar
  • 15 Folprecht G, Gruenberger T, Bechstein BO. et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab. Lancet Oncol 2010; 11: 38-47
    CrossrefPubMedGoogle Scholar
  • 16 Oliner KS, Douillard JY, Siena S. et al. Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC). J Clin Oncol 2013 31. abstr 3511
    PubMedGoogle Scholar
  • 17 Saltz LB, Clarke S, Diaz-Rubio E. et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer. J Clin Oncol 2008; 26: 2013-2019
    CrossrefPubMedGoogle Scholar
  • 18 Seymour MT, Maughan TS, Ledermann JA. et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007; 370: 143-152
    CrossrefPubMedGoogle Scholar
  • 19 Rowland A, Dias MM, Wiese MD. et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer 2015; 112: 1888-1894
    CrossrefPubMedGoogle Scholar
  • 20 Cremolini C, Loupakis F, Antoniotti C. et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015; 16: 1306-1315
    CrossrefPubMedGoogle Scholar
  • 21 Corcoran RB, Atreya CE, Falchook GS. et al. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Oncol 2015; 33: 4023-4031
    CrossrefPubMedGoogle Scholar
  • 22 Kopetz S, McDonough SL, Lenz HJ. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). J Clin Oncol 2017 35. Abstract 520
    PubMedGoogle Scholar
  • 23 Le 1 DT, Uram JN, Wang H. et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015; 372: 2509-2520
    CrossrefPubMedGoogle Scholar
  • 24 Yamauchi M, Morikawa T. et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012; 61: 847-854
    CrossrefPubMedGoogle Scholar
  • 25 von Einem JC, Heinemann V, von Weikersthal LF. et al. Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. J Cancer Res Clin Oncol 2014; 140: 1607-1614
    CrossrefPubMedGoogle Scholar
  • 26 Boisen MK, Johansen JS, Dehlendorff C. et al. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer. Ann Oncol 2013; 24: 2554-2559
    CrossrefPubMedGoogle Scholar
  • 27 Tejpar S, Stintzing S, Ciardiello F. et al. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. JAMA Oncol 2016; DOI: 10.1001/jamaoncol.2016.3797.
    CrossrefPubMedGoogle Scholar
  • 28 Arnold D, Lueza B, Douillard JY. et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomised trials. Ann Oncol 2017; 28: 1713-1729
    CrossrefPubMedGoogle Scholar
  • 29 Loupakis F, Yang D, Yau L. et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst 2015; 107 DOI: 10.1093/jnci/dju427.
    CrossrefPubMedGoogle Scholar